Steven Lazarus's Net Worth
$51 Million
Who is Steven Lazarus?
Steven Lazarus has an estimated net worth of $51 Million. This is based on reported shares across multiple companies, which include ALNYLAM PHARMACEUTICALS INC, IMPINJ INC, NeurogesX Inc, XCYTE THERAPIES INC, AMGEN INC, ILLUMINA INC, XTERA COMMUNICATIONS, INC., Trubion Pharmaceuticals, Inc, CELEBRATE EXPRESS, INC., and FIRST CONSULTING GROUP INC.
SEC CIK
Steven Lazarus's CIK is 0001054117
Past Insider Trading and Trends
2004 was Steven Lazarus's most active year for acquiring shares with 3 total transactions. Steven Lazarus's most active month to acquire stocks was the month of February. 2003 was Steven Lazarus's most active year for disposing of shares, totalling 5 transactions. Steven Lazarus's most active month to dispose stocks was the month of January. 2004 saw Steven Lazarus paying a total of $22,520.00 for 10,643 shares, this is the most they've acquired in one year. In 2003 Steven Lazarus cashed out on 30,000 shares for a total of $1,360,105.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ALNYLAM PHARMACEUTICALS INC (ALNY) Snapshot price: $246.78
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
IMPINJ INC (PI) Snapshot price: $165.4
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
∞
| 1.37M |
$10.73 | $204.50 | 1.37M |
Jul 26
| |||
Form 4
|
∞
| 1.36M |
$11.66 | $68.32 | 1.36M |
Jul 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
NeurogesX Inc No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +71.38% | 1.74M |
$1.65 | $2,877,906.90 | 4.19M |
Jul 21
| |||
Form 4
| +18.54% | 382.17K |
$6.18 | $2,361,810.60 | 2.44M |
Dec 24
| |||
Form 4
| +1,015.12% | 2.3M |
—
|
—
| 2.53M |
May 7
| |||
Form 4
|
∞
| 227K |
$11.00 | $2,497,000.00 | 227K |
May 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
XCYTE THERAPIES INC (CYCC) Snapshot price: $1.02
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 29
| |||
Form 4
|
∞
| 2.05M |
$8.00 | $1,500,000.00 | 2.05M |
Mar 19
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
AMGEN INC (AMGN) Snapshot price: $320.56
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 1.64K |
—
|
—
| 1.64K |
Mar 15
| |||
Form 4
| -6.28% | -10.00K |
$64.22 | -$642,200.00 | 149.34K |
Feb 25
| |||
Form 4
| -5.91% | -10.00K |
$64.01 | -$640,086.56 | 159.34K |
Feb 24
| |||
Form 4
| -5.58% | -10.00K |
—
|
—
| 169.34K |
Nov 21
| |||
Form 4
| -4.78% | -9.00K |
$68.00 | -$612,000.00 | 179.34K |
Sep 8
| |||
Form 4
| -0.53% | -1.00K |
$68.11 | -$68,105.00 | 188.34K |
Sep 3
| |||
Form 4/A
|
—
|
0
|
—
|
—
| 189.34K |
Aug 28
| |||
Form 4
| -5.28% | -10.00K |
$68.00 | -$680,000.00 | 179.34K |
Aug 12
| |||
No matching records found |